| Clomipramine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Clomipramine | hsa00040 | Pentose and glucuronate interconversions | 2.33E-04 | 2 | P15121, P14550 | AKR1B1, AKR1A1 | More | |
| Clomipramine | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | |
| Clomipramine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | |
| Clomipramine | hsa00240 | Pyrimidine metabolism | 4.29E-02 | 2 | P21589, P04183 | NT5E, TK1 | More | |
| Clomipramine | hsa00500 | Starch and sucrose metabolism | 1.67E-02 | 2 | O43451, P06737 | MGAM, PYGL | More | |
| Clomipramine | hsa00513 | Various types of N-glycan biosynthesis | 4.96E-02 | 1 | Q9NR34 | MAN1C1 | More | |
| Clomipramine | hsa00561 | Glycerolipid metabolism | 2.62E-02 | 2 | P15121, P14550 | AKR1B1, AKR1A1 | More | |
| Clomipramine | hsa00564 | Glycerophospholipid metabolism | 4.29E-02 | 2 | Q6P1A2, P23743 | MBOAT5, DGKA | More | |
| Clomipramine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
| Clomipramine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
| Clomipramine | hsa00600 | Sphingolipid metabolism | 3.76E-02 | 1 | P15289 | ARSA | More | |
| Clomipramine | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.87E-03 | 3 | P06865, O15466, Q9H4F1 | HEXA, ST8SIA5, ST6GALNAC4 | More | |
| Clomipramine | hsa00730 | Thiamine metabolism | 5.29E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
| Clomipramine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Clomipramine | hsa00790 | Folate biosynthesis | 2.02E-02 | 1 | P15121 | AKR1B1 | More | |
| Clomipramine | hsa00830 | Retinol metabolism | 3.15E-02 | 1 | P00325 | ADH1B | More | |
| Clomipramine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 6.38E-04 | 3 | P78417, P09211, P11712 | GSTO1, GSTP1, CYP2C9 | More | |
| Clomipramine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
| Clomipramine | hsa00983 | Drug metabolism - other enzymes | 8.33E-04 | 4 | P20839, P32320, P05164, Q16772 | IMPDH1, CDA, MPO, GSTA3 | More | |
| Clomipramine | hsa01100 | Metabolic pathways | 2.59E-02 | 11 | P35790, Q16772, P30041, P20839, O94777, P15121, O95861, P14550, Q9UHK6, Q86VZ5, Q9NVH6 | CHKA, GSTA3, PRDX6, IMPDH1, DPM2, AKR1B1, BPNT1, AKR1A1, AMACR, SGMS1, TMLHE | More | |
| Clomipramine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Clomipramine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Clomipramine | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | |
| Clomipramine | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa01522 | Endocrine resistance | 1.69E-02 | 4 | P22694, P04049, P10415, Q13323 | PRKACB, RAF1, BCL2, BIK | More | |
| Clomipramine | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
| Clomipramine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | |
| Clomipramine | hsa03010 | Ribosome | 1.08E-04 | 11 | P62753, P25398, P32969, P40429, P62829, Q07020, P18077, P36578, P27635, P05386, P62249 | RPS6, RPS12, RPL9, RPL13A, RPL23, RPL18, RPL35A, RPL4, RPL10, RPLP1, RPS16 | More | |
| Clomipramine | hsa03020 | RNA polymerase | 1.27E-04 | 3 | P30876, P24928, P62487 | POLR2B, POLR2A, POLR2G | More | |
| Clomipramine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
| Clomipramine | hsa03320 | PPAR signaling pathway | 4.33E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | |
| Clomipramine | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | |
| Clomipramine | hsa03430 | Mismatch repair | 4.38E-02 | 1 | P20585 | MSH3 | More | |
| Clomipramine | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04012 | ErbB signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04014 | Ras signaling pathway | 3.65E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04015 | Rap1 signaling pathway | 3.75E-04 | 7 | P04049, P06213, P25116, Q8TEU7, O00522, P08514, P17252 | RAF1, INSR, F2R, RAPGEF6, KRIT1, ITGA2B, PRKCA | More | |
| Clomipramine | hsa04022 | cGMP-PKG signaling pathway | 6.45E-03 | 5 | P04049, P18848, Q8WYR1, P05141, P0DP24 | RAF1, ATF4, PIK3R5, SLC25A5, CALM2 | More | |
| Clomipramine | hsa04024 | cAMP signaling pathway | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04062 | Chemokine signaling pathway | 3.98E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04064 | NF-kappa B signaling pathway | 4.58E-03 | 4 | Q13489, Q13546, Q9UDY8, Q9UNE0 | BIRC3, RIPK1, MALT1, EDAR | More | |
| Clomipramine | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04071 | Sphingolipid signaling pathway | 1.79E-04 | 6 | P04049, P21453, Q9H228, P01375, Q13362, Q9UQC2 | RAF1, S1PR1, EDG8, TNF, PPP2R5C, GAB2 | More | |
| Clomipramine | hsa04072 | Phospholipase D signaling pathway | 2.82E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04080 | Neuroactive ligand-receptor interaction | 2.95E-04 | 8 | P08311, P28472, Q15722, P21453, Q9H228, O00398, P21730, P07550 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, ADRB2 | More | |
| Clomipramine | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | |
| Clomipramine | hsa04114 | Oocyte meiosis | 6.23E-03 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | |
| Clomipramine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Clomipramine | hsa04140 | Autophagy - animal | 2.81E-02 | 4 | P04049, P22694, Q14643, P10415 | RAF1, PRKACB, ITPR1, BCL2 | More | |
| Clomipramine | hsa04141 | Protein processing in endoplasmic reticulum | 4.88E-02 | 4 | P18848, O60337, P11142, P07900 | ATF4, MARH6, HSPA8, HSP90AA1 | More | |
| Clomipramine | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04151 | PI3K-Akt signaling pathway | 7.39E-03 | 7 | P62753, O43521, P27348, Q8WYR1, P18848, O00141, Q6ZUJ8 | RPS6, BCL2L11, YWHAQ, PIK3R5, ATF4, SGK, PIK3AP1 | More | |
| Clomipramine | hsa04210 | Apoptosis | 6.94E-04 | 8 | O76075, P01375, Q9NR28, O75460, Q16548, O43521, P18848, P04049 | DFFB, TNF, DIABLO, ERN1, BCL2A1, BCL2L11, ATF4, RAF1 | More | |
| Clomipramine | hsa04211 | Longevity regulating pathway | 1.18E-02 | 3 | Q12778, Q9UEF7, Q96KQ7 | FOXO1, KL, EHMT2 | More | |
| Clomipramine | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | |
| Clomipramine | hsa04217 | Necroptosis | 7.81E-08 | 14 | P01375, P01568, P48023, Q13489, Q13546, Q14765, P07900, P15104, P05141, P01584, P0C0S5, Q99878, Q13557, Q9H444 | TNF, IFNA21, FASLG, BIRC3, RIPK1, STAT4, HSP90AA1, GLUL, SLC25A5, IL1B, H2AFZ, H2AC14, CAMK2D, CHMP4B | More | |
| Clomipramine | hsa04218 | Cellular senescence | 8.08E-03 | 5 | P01106, P04049, O75293, P30304, P06493 | MYC, RAF1, GADD45B, CDC25A, CDK1 | More | |
| Clomipramine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
| Clomipramine | hsa04270 | Vascular smooth muscle contraction | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04340 | Hedgehog signaling pathway | 7.27E-04 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | |
| Clomipramine | hsa04360 | Axon guidance | 2.49E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04370 | VEGF signaling pathway | 2.77E-04 | 4 | P16298, Q05397, Q02750, P04049 | PPP3CB, PTK2, MAP2K1, RAF1 | More | |
| Clomipramine | hsa04371 | Apelin signaling pathway | 2.65E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
| Clomipramine | hsa04540 | Gap junction | 5.06E-03 | 4 | P22694, P68371, P04049, Q14643 | PRKACB, TUBB2C, RAF1, ITPR1 | More | |
| Clomipramine | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 9.61E-03 | 4 | Q13873, P04049, Q02750, Q86SE9 | BMPR2, RAF1, MAP2K1, PCGF5 | More | |
| Clomipramine | hsa04610 | Complement and coagulation cascades | 2.78E-03 | 1 | P0C0L4 | C4A | More | |
| Clomipramine | hsa04611 | Platelet activation | 3.39E-02 | 3 | P25116, P08514, P07359 | F2R, ITGA2B, GP1BA | More | |
| Clomipramine | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Clomipramine | hsa04613 | Neutrophil extracellular trap formation | 1.62E-06 | 12 | P04049, P11215, Q13547, P04908, Q93077, P58876, P62807, Q16778, O60814, P68431, O43315, Q16539 | RAF1, ITGAM, HDAC1, H2AC4; H2AC8, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | |
| Clomipramine | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | |
| Clomipramine | hsa04621 | NOD-like receptor signaling pathway | 4.72E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | |
| Clomipramine | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | |
| Clomipramine | hsa04623 | Cytosolic DNA-sensing pathway | 2.20E-03 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | |
| Clomipramine | hsa04625 | C-type lectin receptor signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04630 | JAK-STAT signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04640 | Hematopoietic cell lineage | 3.69E-02 | 4 | P21926, P07766, P01730, P09564 | CD9, CD3E, CD4, CD7 | More | |
| Clomipramine | hsa04650 | Natural killer cell mediated cytotoxicity | 5.84E-06 | 11 | P16298, P50591, P01375, P20963, Q02750, P04049, Q13241, P26718, P26717, Q14953, P26715 | PPP3CB, TNFSF10, TNF, CD247, MAP2K1, RAF1, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
| Clomipramine | hsa04657 | IL-17 signaling pathway | 2.73E-04 | 7 | P07900, P49841, P19875, P14780, P80188, P01375, P01584 | HSP90AA1, GSK3B, CXCL2, MMP9, LCN2, TNF, IL1B | More | |
| Clomipramine | hsa04660 | T cell receptor signaling pathway | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04662 | B cell receptor signaling pathway | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04664 | Fc epsilon RI signaling pathway | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04666 | Fc gamma R-mediated phagocytosis | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04668 | TNF signaling pathway | 2.67E-03 | 6 | P01375, P18848, P19875, P01584, P14780, P20333 | TNF, ATF4, CXCL2, IL1B, MMP9, TNFRSF1B | More | |
| Clomipramine | hsa04672 | Intestinal immune network for IgA production | 1.35E-02 | 2 | P29965, P13765 | CD40LG, HLA-DOB | More | |
| Clomipramine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
| Clomipramine | hsa04720 | Long-term potentiation | 4.88E-03 | 4 | P16298, P51812, Q02750, P04049 | PPP3CB, RPS6KA3, MAP2K1, RAF1 | More | |
| Clomipramine | hsa04722 | Neurotrophin signaling pathway | 7.10E-03 | 4 | P04049, P49841, O43524, P48023 | RAF1, GSK3B, FOXO3, FASLG | More | |
| Clomipramine | hsa04725 | Cholinergic synapse | 3.74E-02 | 3 | P22694, Q14643, P10415 | PRKACB, ITPR1, BCL2 | More | |
| Clomipramine | hsa04726 | Serotonergic synapse | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04730 | Long-term depression | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
| Clomipramine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
| Clomipramine | hsa04810 | Regulation of actin cytoskeleton | 3.81E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04910 | Insulin signaling pathway | 2.51E-03 | 4 | P22694, P06737, P04049, P49841 | PRKACB, PYGL, RAF1, GSK3B | More | |
| Clomipramine | hsa04912 | GnRH signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04913 | Ovarian steroidogenesis | 1.51E-04 | 3 | P42330, P22694, P06213 | AKR1C3, PRKACB, INSR | More | |
| Clomipramine | hsa04914 | Progesterone-mediated oocyte maturation | 1.91E-03 | 5 | Q17RY0, Q9Y6D9, P51812, Q02750, P04049 | CPEB4, MAD1L1, RPS6KA3, MAP2K1, RAF1 | More | |
| Clomipramine | hsa04915 | Estrogen signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04916 | Melanogenesis | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04917 | Prolactin signaling pathway | 6.63E-03 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04918 | Thyroid hormone synthesis | 3.16E-02 | 2 | P17252, P27824 | PRKCA, CANX | More | |
| Clomipramine | hsa04919 | Thyroid hormone signaling pathway | 6.83E-04 | 5 | P49841, P04049, P22694, O60244, Q9NVC6 | GSK3B, RAF1, PRKACB, MED14, MED17 | More | |
| Clomipramine | hsa04921 | Oxytocin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04923 | Regulation of lipolysis in adipocytes | 3.76E-02 | 1 | P06213 | INSR | More | |
| Clomipramine | hsa04924 | Renin secretion | 2.90E-04 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | |
| Clomipramine | hsa04926 | Relaxin signaling pathway | 6.24E-03 | 5 | P18848, P22694, P14780, P04049, P30679 | ATF4, PRKACB, MMP9, RAF1, GNA15 | More | |
| Clomipramine | hsa04927 | Cortisol synthesis and secretion | 1.27E-03 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | |
| Clomipramine | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.75E-03 | 5 | Q14643, P22694, P23771, P04049, P10415 | ITPR1, PRKACB, GATA3, RAF1, BCL2 | More | |
| Clomipramine | hsa04929 | GnRH secretion | 4.98E-03 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04930 | Type II diabetes mellitus | 3.14E-02 | 1 | P06213 | INSR | More | |
| Clomipramine | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | |
| Clomipramine | hsa04932 | Non-alcoholic fatty liver disease | 4.65E-07 | 11 | P01375, P49841, O43521, P18848, P48023, O75460, P01584, P13073, O15239, Q16718, O14521 | TNF, GSK3B, BCL2L11, ATF4, FASLG, ERN1, IL1B, COX4I1, NDUFA1, NDUFA5, SDHD | More | |
| Clomipramine | hsa04934 | Cushing syndrome | 4.74E-02 | 3 | Q14643, P22694, P04628 | ITPR1, PRKACB, WNT1 | More | |
| Clomipramine | hsa04935 | Growth hormone synthesis, secretion and action | 2.16E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Clomipramine | hsa04960 | Aldosterone-regulated sodium reabsorption | 3.14E-02 | 1 | P06213 | INSR | More | |
| Clomipramine | hsa04966 | Collecting duct acid secretion | 1.68E-02 | 2 | P02730, P00918 | SLC4A1, CA2 | More | |
| Clomipramine | hsa04970 | Salivary secretion | 9.44E-04 | 4 | P07550, P22694, Q14643, P49913 | ADRB2, PRKACB, ITPR1, CAMP | More | |
| Clomipramine | hsa04972 | Pancreatic secretion | 1.31E-02 | 2 | Q08828, P62491 | ADCY1, RAB11A | More | |
| Clomipramine | hsa04975 | Fat digestion and absorption | 2.80E-02 | 1 | O14494 | PLPP1 | More | |
| Clomipramine | hsa04976 | Bile secretion | 1.67E-03 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | |
| Clomipramine | hsa05010 | Alzheimer disease | 2.78E-02 | 6 | P13073, O75460, P0DP24, P01584, P18848, P05141 | COX4I1, ERN1, CALM2, IL1B, ATF4, SLC25A5 | More | |
| Clomipramine | hsa05012 | Parkinson disease | 2.77E-03 | 7 | O15239, P13073, P05141, O75460, P18848, P0DP24, Q13557 | NDUFA1, COX4I1, SLC25A5, ERN1, ATF4, CALM2, CAMK2D | More | |
| Clomipramine | hsa05016 | Huntington disease | 4.33E-03 | 7 | O15239, P13073, P24928, P30876, P62487, P05141, O75460 | NDUFA1, COX4I1, POLR2A, POLR2B, POLR2G, SLC25A5, ERN1 | More | |
| Clomipramine | hsa05020 | Prion disease | 3.73E-04 | 11 | P13591, P01584, P11142, O15239, Q16718, O14521, P13073, P18848, P05141, P49841, Q16539 | NCAM1, IL1B, HSPA8, NDUFA1, NDUFA5, SDHD, COX4I1, ATF4, SLC25A5, GSK3B, MAPK14 | More | |
| Clomipramine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 9.19E-05 | 15 | P49841, O15239, Q16718, O14521, P13073, O75460, P18848, Q13561, P05141, P20333, Q16539, P01584, Q08752, P0DP24, Q13557 | GSK3B, NDUFA1, NDUFA5, SDHD, COX4I1, ERN1, ATF4, DCTN2, SLC25A5, TNFRSF1B, MAPK14, IL1B, PPID, CALM2, CAMK2D | More | |
| Clomipramine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Clomipramine | hsa05034 | Alcoholism | 1.81E-06 | 8 | Q13547, P04049, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, RAF1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Clomipramine | hsa05100 | Bacterial invasion of epithelial cells | 2.85E-02 | 3 | Q14141, Q05397, Q96JJ3 | SEPT6, PTK2, ELMO2 | More | |
| Clomipramine | hsa05132 | Salmonella infection | 2.71E-03 | 5 | P04049, Q13546, Q13489, O60282, P68371 | RAF1, RIPK1, BIRC3, KIF5C, TUBB2C | More | |
| Clomipramine | hsa05133 | Pertussis | 4.94E-02 | 1 | P0C0L4 | C4A | More | |
| Clomipramine | hsa05134 | Legionellosis | 1.28E-02 | 3 | P01584, P68104, P11142 | IL1B, EEF1A1, HSPA8 | More | |
| Clomipramine | hsa05135 | Yersinia infection | 3.29E-02 | 4 | Q05397, P51812, Q02750, Q96JJ3 | PTK2, RPS6KA3, MAP2K1, ELMO2 | More | |
| Clomipramine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
| Clomipramine | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | |
| Clomipramine | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
| Clomipramine | hsa05152 | Tuberculosis | 3.98E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05160 | Hepatitis C | 1.40E-03 | 5 | P60033, P04049, P49841, P01375, P48023 | CD81, RAF1, GSK3B, TNF, FASLG | More | |
| Clomipramine | hsa05161 | Hepatitis B | 1.99E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05162 | Measles | 4.02E-02 | 3 | P11142, P01584, Q9NP90 | HSPA8, IL1B, RAB9B | More | |
| Clomipramine | hsa05163 | Human cytomegalovirus infection | 4.98E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05164 | Influenza A | 3.65E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05170 | Human immunodeficiency virus 1 infection | 3.48E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05171 | Coronavirus disease - COVID-19 | 6.98E-05 | 12 | P01584, P62753, P25398, P62249, P40429, P36578, P32969, P27635, Q07020, P18077, P05386, P62829 | IL1B, RPS6, RPS12, RPS16, RPL13A, RPL4, RPL9, RPL10, RPL18, RPL35A, RPLP1, RPL23 | More | |
| Clomipramine | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | |
| Clomipramine | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | |
| Clomipramine | hsa05204 | Chemical carcinogenesis | 1.09E-03 | 3 | P09211, P78417, P11712 | GSTP1, GSTO1, CYP2C9 | More | |
| Clomipramine | hsa05205 | Proteoglycans in cancer | 1.38E-03 | 10 | Q12955, P04049, Q14247, P14780, P17252, P01375, P23588, Q13635, P22694, P08962 | ANK3, RAF1, CTTN, MMP9, PRKCA, TNF, EIF4B, PTCH1, PRKACB, CD63 | More | |
| Clomipramine | hsa05206 | MicroRNAs in cancer | 3.15E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05210 | Colorectal cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05211 | Renal cell carcinoma | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05212 | Pancreatic cancer | 1.16E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05213 | Endometrial cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05214 | Glioma | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | |
| Clomipramine | hsa05218 | Melanoma | 9.63E-04 | 4 | P09619, Q9GZP0, Q02750, P04049 | PDGFRB, PDGFD, MAP2K1, RAF1 | More | |
| Clomipramine | hsa05219 | Bladder cancer | 4.98E-03 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05220 | Chronic myeloid leukemia | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05221 | Acute myeloid leukemia | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05223 | Non-small cell lung cancer | 6.95E-04 | 4 | P10826, P04049, Q9HC35, O75293 | RARB, RAF1, EML4, GADD45B | More | |
| Clomipramine | hsa05224 | Breast cancer | 1.49E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05226 | Gastric cancer | 8.29E-03 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05230 | Central carbon metabolism in cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
| Clomipramine | hsa05231 | Choline metabolism in cancer | 1.49E-03 | 5 | Q02750, P04049, P09619, Q9GZP0, O15245 | MAP2K1, RAF1, PDGFRB, PDGFD, SLC22A1 | More | |
| Clomipramine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.21E-03 | 5 | P07766, P06239, P04049, Q9HC35, P01730 | CD3E, LCK, RAF1, EML4, CD4 | More | |
| Clomipramine | hsa05310 | Asthma | 1.35E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
| Clomipramine | hsa05320 | Autoimmune thyroid disease | 3.16E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
| Clomipramine | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Clomipramine | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Clomipramine | hsa05330 | Allograft rejection | 1.76E-03 | 4 | P13765, P29965, P48023, P01375 | HLA-DOB, CD40LG, FASLG, TNF | More | |
| Clomipramine | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
| Clomipramine | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | |
| Clomipramine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 1.49E-03 | 6 | Q8IZS8, P54284, P14923, P08514, P13612, Q9UJU2 | CACNA2D3, CACNB3, JUP, ITGA2B, ITGA4, LEF1 | More | |
| Clomipramine | hsa05414 | Dilated cardiomyopathy | 2.11E-02 | 4 | Q8IZS8, P54284, P13612, P26678 | CACNA2D3, CACNB3, ITGA4, PLN | More | |
| Clomipramine | hsa05415 | Diabetic cardiomyopathy | 1.02E-03 | 8 | P05141, O15239, Q16718, O14521, P13073, Q16539, P49841, Q13557 | SLC25A5, NDUFA1, NDUFA5, SDHD, COX4I1, MAPK14, GSK3B, CAMK2D | More | |
| Clomipramine | hsa05416 | Viral myocarditis | 4.29E-02 | 2 | P13765, P29965 | HLA-DOB, CD40LG | More | |
